COMMUNIQUÉS West-GlobeNewswire

TME Pharma publie ses résultats semestriels et son rapport semestriel
30/10/2026
TME Pharma publie ses résultats semestriels et son rapport semestriel Berlin, Allemagne, le 30 octobre 2026, 18 h 00 CET – TME Pharma N.V. (Euronext Growth Paris : ALTME), une société de biotechnologie disposant d' [...]
TME Pharma Publishes Its Semi Annual Results and Half-Year Report
30/10/2026
TME Pharma Publishes Its Semi Annual Results and Half-Year Report Berlin, Germany , October 30, 2026, 18:00 CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotech-company with clinical assets for brain cancer [...]
Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan
30/10/2026
WOODCLIFF LAKE, N.J., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has adopted an amendment (the “ [...]
Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue
30/10/2026
- Agreement complements revenue from standard gene expression and DRP® services - Development and validation services will support a European biotechnology company’s precision oncology predictive device for use in the [...]
Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study
30/10/2026
Interim Results in Super-Aged Rats Tested Externally Show Preserved Motor Performance and Reduced Fat Mass, Consistent with Prior Findings in Aged Mice Tested at Eos’s R&D Facility; Data Support IND-Enabling [...]
Profound Medical and Cook Medical’s iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth
30/10/2026
New distribution agreement positions TULSA-PRO within the iMRI Suite offering through Cook Medical’s Copernicus™ program, expanding Profound’s commercial reach Profound retains direct TULSA-PRO recurring treatment kit [...]
Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
30/10/2026
Completed enrollment in Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis; topline results remain on track for 1H27 Expanded telitacicept franchise into ocular myasthenia gravis with Phase 3 [...]
Aer Therapeutics Announces Top-Line Results from its Phase 2a Proof-of-Concept Trial of Fexlamose in Chronic Obstructive Pulmonary Disease (“COPD”)
30/10/2026
90 mg dose of fexlamose administered daily via nebulizer did not demonstrate improvement on trough FEV1, FVC and other spirometric measures with 28 days of dosing in moderate to severe COPD patients. Fexlamose did not [...]
Canon Medical and Stereotaxis Collaborate to Advance Robotic Electrophysiology
30/10/2026
Collaboration brings together Canon’s Alphenix interventional fluoroscopy system and Stereotaxis’ GenesisX robotic technology Technologies will be presented at TCT 2026 in the Canon booth TUSTIN, Calif. and ST. LOUIS, [...]
Polk County Mosquito Control Reduces Aedes aegypti by Up to 95% with Sterile Insect Farms™ Sterile Male Releases
30/10/2026
BUFORD, Ga., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Polk County Mosquito Control has reduced populations of Aedes aegypti (its top problem species and a primary carrier of dengue, Zika, and chikungunya) by up to 95% after [...]
NurExone Demonstrates Consistent Anti-Inflammatory Activity Across Three Separate Batches of Exosomes
30/10/2026
New results strengthen the foundation for commercial naïve exosome supply and continued development of ExoPTEN TORONTO and HAIFA, Israel, Oct. 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: [...]
Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients
30/10/2026
MELBOURNE, Australia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases [...]
IRADIMED CORPORATION Reports Third Quarter 2026 Financial Results
30/10/2026
Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reports revenue of $24.2 million for the third quarter of 2026, which increased by $3.0 million, or 14% compared to the same period in 2025 and increased by $ [...]
Sienna Completes Acquisition in Ottawa
30/10/2026
MARKHAM, Ontario, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (" Sienna " or the " Company ") (TSX: SIA) announced today that it has completed its previously disclosed $170.7 million acquisition of [...]
Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting
30/10/2026
PRINCETON, N.J., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026 Congress of Neurological [...]
Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting
30/10/2026
WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated [...]
Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum
30/10/2026
Latest $1.5 Million Installment Reflects Continued Milestone Progress as DARE-LARC1 Advances in Preclinical Development Company Exploring Potential Strategic Collaborations for DARE-IDDS Platform in Obesity, Diabetes [...]
CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides
30/10/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 30, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) ("CDT" or the "Company"), today welcomed a significant development in the U.S. regulatory landscape for [...]
Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027
30/10/2026
Milestone underscores execution of pivotal Phase 2/3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML) Fully treated, randomized, double-blind n=90 Part A [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum